Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31452756 | 0.76 | CYP2A6 (0.60) | CYP2A6ALDH1A1 | |
| SCHEMBL274426 | 0.76 | CYP2A6 (0.60) | CYP2A6ALDH1A1 | |
| SCHEMBL21617927 | 0.75 | ALDH1A1 (0.45) | CYP2A6ALDH1A1HPGD | |
| SCHEMBL3150232 | 0.75 | CYP2A6 (0.59) | CYP19A1TBXAS1CYP2A6ADRA2AADRA2B | |
| SCHEMBL506756 | 0.75 | CYP2A6 (0.57) | CYP19A1TBXAS1CYP2A6ADRA2AADRA2B | |
| SCHEMBL3798556 | 0.75 | CYP19A1 (0.46) | CYP19A1TBXAS1OPRM1OPRK1 | |
| SCHEMBL2092142 | 0.75 | CYP19A1 (0.46) | CYP19A1TBXAS1CYP2A6ADRA2AADRA2B | |
| SCHEMBL30287240 | 0.75 | CYP2A6 (0.59) | CYP19A1TBXAS1CYP2A6ADRA2AADRA2B | |
| SCHEMBL20562508 | 0.72 | CYP19A1 (0.51) | CYP19A1TBXAS1CYP2A6OPRM1OPRK1 | |
| SCHEMBL48087 | 0.72 | CYP19A1 (0.51) | CYP19A1TBXAS1CYP2A6ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-12-01 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-04-23 | — | — | US | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294792-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | CYP19A1 3573/4885TBXAS1 654/4885CYP2A6 2565/4885 |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | CYP19A1 3573/4885TBXAS1 654/4885CYP2A6 2565/4885 |
| US-20090105229-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | CYP19A1 3573/4885TBXAS1 654/4885CYP2A6 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.